Natural Treg in autoimmune diabetes: All present and correct?

Expert Opinion on Biological Therapy

Volumn 8, Issue 11, 2008, Pages 1691-1703

  Walker, Lucy S K ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Autoimmunity; Mouse models; Regulatory T cells; Type 1 diabetes

Indexed keywords

C PEPTIDE; CD3 ANTIBODY; HEMAGGLUTININ; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MONOCLONAL ANTIBODY CD3; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL POPULATION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE FUNCTION; NONHUMAN; NONOBESE DIABETIC MOUSE; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; ANTIGENS; ANTIGENS, CD4; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE SYSTEM; INSULIN; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, INBRED NOD; MODELS, BIOLOGICAL; PROMOTER REGIONS, GENETIC; RATS; T-LYMPHOCYTES, REGULATORY;

EID: 56249117354     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.11.1691     Document Type: Review

References (136)

1. Bohme J, Haskins K, Stecha P, et al. Transgenic mice with I-A on islet cells are normoglycemic but immunologically intolerant. Science 1989;244:1179-83
2. Burkly LC, Lo D, Flavell RA. Tolerance in transgenic mice expressing major histocompatibility molecules extrathymically on pancreatic cells. Science 1990;248:1364-8
3. + T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med 1990;172:1701-8
4. + T cells: a population of T cells with immune regulatory activities in vitro. Eur J Immunol 1998;28:3435-47
5. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64
6. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 1996;184:387-96
7. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998;160:1212-8
8. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-96
9. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985;161:72-87
10. Sakaguchi S, Takahashi T, Nishizuka Y. Study on cellular events in post-thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis. J Exp Med 1982;156:1577-86
11. Seddon B, Mason D. Peripheral autoantigen induces regulatory T cells that prevent autoimmunity. J Exp Med 1999;189:877-82
12. + T regulatory cells. Nat Immunol 2003; 4:337-42
13. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61
14. + regulatory T cells. Nat Immunol 2003;4:330-6
15. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/ winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001;27:68-73
16. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20
17. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-1
18. Torgerson TR. Regulatory T cells in human autoimmune diseases. Springer Semin Immunopathol 2006;28:63-76
19. Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006;116:1713-22
20. Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007;445:771-5
21. Hill JA, Feuerer M, Tash K, et al. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 2007;27:786-800
22. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007;8:191-7
23. Makino S, Kunimoto K, Muraoka Y, et al. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980;29:1-13
24. Giarratana N, Penna G, Adorini L. Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse. Methods Mol Biol 2007;380:285-311
25. Yu L, Robles DT Abiru N, et al. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci USA 2000;97:1701-6
26. Green EA, Eynon EE, Flavell RA. Local expression of TNFα in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity 1998;9:733-43
27. Katz JD, Wang B, Haskins K, et al. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993;74:1089-100
28. Wong FS, Visintin I, Wen L, et al. The role of lymphocyte subsets in accelerated diabetes in nonobese diabetic-rat insulin promoter-B7-1 (NOD-RIP-B7-1) mice. J Exp Med 1998;187:1985-93
29. Gonzalez A, Katz JD, Mattei MG, et al. Genetic control of diabetes progression. Immunity 1997;7:873-83
30. von Herrath MG, Dockter J, Oldstone MB. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1994;1:231-42
31. Oldstone MB, Nerenberg M, Southern P, et al. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991;65:319-31
32. Chao CC, Sytwu HK, Chen EL, et al. The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. Proc Natl Acad Sci USA 1999;96:9299-304
33. Ohashi PS, Oehen S, Buerki K, et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305-17
34. Ehl S, Hombach J, Aichele P, et al. Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med 1997;185:1241-51
35. + T cells. Eur J Immunol 1992;22:1013-22
36. Sarukhan A, Lanoue A, Franzke A, et al. Changes in function of antigen-specific lymphocytes correlating with progression towards diabetes in a transgenic model. EMBO J 1998;17:71-80
37. Walter U, Franzke A, Sarukhan A, et al. Monitoring gene expression of TNFR family members by β-cells during development of autoimmune diabetes. Eur J Immunol 2000;30:1224-32
38. Degermann S, Reilly C, Scott B, et al. On the various manifestations of spontaneous autoimmune diabetes in rodent models. Eur J Immunol 1994;24:3155-60
39. + T cells specific for a pancreatic beta cell neo-antigen. Immunity 1995;2:573-85
40. Apostolou I, Von Boehmer H. The TCR-HA, INS-HA transgenic model of autoimmune diabetes: limitations and expectations. J Autoimmun 2004;22:111-4
41. Sarukhan A, Lechner O, von Boehmer H. Autoimmune insulitis and diabetes in the absence of antigen-specific contact between T cells and islet beta-cells. Eur J Immunol 1999;29:3410-6
42. Kurts C, Heath WR, Carbone FR, et al. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996;184:923-30
43. Clough LE, Wang CJ, Schmidt EM, et al. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J Immunol 2008;180:5393-401
44. Andre I, Gonzalez A, Wang B, et al. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc Natl Acad Sci USA 1996;93:2260-3
45. Signore A, Pozzilli P, Gale EA, et al. The natural history of lymphocyte subsets infiltrating the pancreas of NOD mice. Diabetologia 1989;32:282-9
46. Bottazzo GF, Dean BM, McNally JM, et al. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med 1985;313:353-60
47. Boitard C, Yasunami R, Dardenne M, Bach JF. T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med 1989;169:1669-80
48. + β islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice. J Exp Med 1995;182:87-97
49. + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:431-40
50. + regulatory T cells. Immunology 2007;121:15-28
51. + regulatory T cells in vivo J Exp Med 2003;198:249-58
52. + regulatory T cells. J Immunol 2006;177:6603-12
53. Harada M, Makino S. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia 1984;27:604-6
54. Yasunami R, Bach JF. Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol 1988;18:481-4
55. + splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 2002;169:2461-5
56. + regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci USA 2004;101(Suppl 2):14580-5
57. + cells controlling a pathogenic CD4 response inhibit cytokine differentiation, CXCR-3 expression, and tissue invasion. J Immunol 2004;173:2942-51
58. Tang Q, Adams JY, Tooley AJ, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006;7:83-92
59. Billiard F, Litvinova E, Saadoun D, et al. Regulatory and effector T cell activation levels are prime determinants of in vivo immune regulation. J Immunol 2006;177:2167-74
60. Danke NA, Koelle DM, Yee C, et al. Autoreactive T cells in healthy individuals. J Immunol 2004;172:5967-72
61. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965;14:619-33
62. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988;318:663-70
63. Hanafusa T, Miyazaki A, Miyagawa J, et al. Examination of islets in the pancreas biopsy specimens from newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 1990;33:105-11
64. Wu AJ, Hua H, Munson SH, McDevitt HO. Tumor necrosis factor-α regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci USA 2002;99:12287-92
65. Berzins SP, Venanzi ES, Benoist C, Mathis D. T-cell compartments of prediabetic nod mice. Diabetes 2003;52:327-34
66. Tritt M, Sgouroudis E, d'Hennezel E, et al. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 2008;57:113-23
67. Feuerer M, Jiang W, Holler PD, et al. Enhanced thymic selection of FoxP3+ regulatory T cells in the NOD mouse model of autoimmune diabetes. Proc Natl Acad Sci USA 2007;104:18181-6
68. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004;117:265-77
69. Pop SM, Wong CP, Culton DA, et al. Single cell analysis shows decreasing FoxP3 and TGFβ1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J Exp Med 2005;201:1333-46
70. Gregori S, Giarratana N, Smiroldo S, Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 2003;171:4040-7
71. Thomas DC, Mellanby RJ, Phillips JM, Cooke A. An early age-related increase in the frequency of CD4+ Foxp3+ cells in BDC2.5NOD mice. Immunology 2007;121:565-76
72. Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008;28:687-97
73. Yamanouchi J, Rainbow D, Serra P, et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 2007;39:329-37
74. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002;109:131-40
75. Putnam AL, Vendrame F, Dotta F, Gottlieb PA. CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun 2005;24:55-62
76. Lindley S, Dayan CM, Bishop A, et al. Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes 2005;54:92-9
77. Brusko TM, Wasserfall CH, Clare-Salzler MJ, et al. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005;54:1407-14
78. Brusko T, Wasserfall C, McGrail K, et al. No alterations in the frequency of FOXP3+ regulatory T-cells in Type 1 diabetes. Diabetes 2007;56:604-12
79. Tree TI, Roep BO, Peakman M. A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T cell Workshop. Ann NY Acad Sci 2006;1079:9-18
80. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701-11
81. Yang Z, Zhou Z, Huang G, et al. The CD4+ regulatory T-cells is decreased in adults with latent autoimmune diabetes. Diabetes Res Clin Pract 2007;76:126-31
82. You S, Belghith M, Cobbold S, et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 2005;54:1415-22
83. Gregg RK, Jain R, Schoenleber SJ, et al. A sudden decline in active membrane-bound TGF-β impairs both T regulatory cell function and protection against autoimmune diabetes. J Immunol 2004;173:7308-16
84. Fahlen L, Read S, Gorelik L, et al. T cells that cannot respond to TGF-β escape control by CD4+CD25+ regulatory T cells. J Exp Med 2005;201:737-46
85. Alard P, Manirarora JN, Parnell SA, et al. Deficiency in NOD antigen-presenting cell function may be responsible for suboptimal CD4+CD25+ T-cell-mediated regulation and type 1 diabetes development in NOD mice. Diabetes 2006;55:2098-105
86. Walker LS. CD4+ CD25+ Treg: divide and rule? Immunology 2004;111:129-37
87. McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 2005;175:3025-32
88. van Amelsfort JM, Jacobs KM, Bijlsma JW, et al. CD4+CD25 + regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004;50:2775-85
89. Suvas S, Kumaraguru U, Pack CD, et al. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med 2003;198:889-901
90. Baecher-Allan C, Viglietta V, Hafler DA. Inhibition of human CD4+CD25+high regulatory T cell function. J Immunol 2002;169:6210-7
91. Green EA, Gorelik L, McGregor CM, et al. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-β-TGF-β receptor interactions in type 1 diabetes. Proc Natl Acad Sci USA 2003;100:10878-83
92. Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are required for priming of β cell reactive T cells in NOD mice. J Exp Med 2002;196:369-77
93. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408:57-63
94. Peluso I, Fantini MC, Fina D, et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007;178:732-9
95. Asano K, Ikegami H, Fujisawa T, et al. Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum Immunol 2007;68:384-91
96. Tarbell KV, Yamazaki S, Olson K, et al. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004;199:1467-77
97. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004;199:1455-65
98. Tarbell KV, Petit L, Zuo X, et al. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 2007;204:191-201
99. Yamazaki S, Iyoda T, Tarbell K, et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003;198:235-47
100. Hoffmann P, Eder R, Kunz-Schughart LA, et al. Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells. Blood 2004;104:895-903
101. Levings MK, Sangregorio R, Roncarolo MG. Human CD25+CD4+ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193:1295-302
102. Thomas AK, Maus MV, Shalaby WS, et al. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol 2002;105:259-72
103. Godfrey WR, Ge YG, Spoden DJ, et al. In vitro-expanded human CD4+CD25+ T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004;104:453-61
104. Earle KE, Tang Q, Zhou X, et al. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin Immunol 2005;115:3-9
105. Haller MJ, Viener HL, Wasserfall C, et al. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol 2008;36:710-5
106. Cobbold S, Waldmann H. Infectious tolerance. Curr Opin Immunol 1998;10:518-24
107. Awasthi A, Carrier Y, Peron JP, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007;8:1380-9
108. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-42
109. Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002;195:603-16
110. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003;198:1875-86
111. Fantini MC, Becker C, Monteleone G, et al. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004;172:5149-53
112. Fu S, Zhang N, Yopp AC, et al. TGF-β induces Foxp3+ T-regulatory cells from CD4+ CD25- precursors. Am J Transplant 2004;4:1614-27
113. Yang L, Anderson DE, Baecher-Allan C, et al. IL-21 and TGF-β are required for differentiation of human T(H) 17 cells. Nature 2008;454:350-2
114. Richer MJ, Straka N, Fang D, et al. Regulatory T-cells protect from type 1 diabetes after induction by coxsackievirus infection in the context of transforming growth factor-beta. 2008;57:1302-11
115. Apostolou I, von Boehmer, H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004;199:1401-8
116. Kretschmer K, Apostolou I, Hawiger D, et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005;6:1219-27
117. Herold KC, Hagopian, W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-8
118. Smith JA, Tang Q, Bluestone JA. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 1998;160:4841-9
119. Smith JA, Tso JY, Clark MR, et al. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997;185:1413-22
120. Hirsch R, Gress RE, Pluznik DH, et al. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol 1989;142:737-43
121. Chatenoud L, Thervet E, Primo J, Bach JF. [Remission of established disease in diabetic NOD mice induced by anti-CD3 monoclonal antibody]. C R Acad Sci III 1992;315:225-8
122. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91:123-7
123. Herold KC, Bluestone JA, Montag AG, et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992;41:385-91
124. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-9
125. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608
126. Herold KC, Burton JB, Francois F, et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). J Clin Invest 2003;111:409-18
127. Belghith M, Bluestone JA, Barriot S, et al. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9:1202-08
128. You S, Leforban B, Garcia C, et al. Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci USA 2007; 104:6335-40
129. Bresson D, Togher L, Rodrigo E, et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006;116:1371-81
130. Koulmanda M, Budo E, Bonner-Weir S, et al. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci USA 2007;104:13074-9
131. Li XC, Demirci G, Ferrari-Lacraz S, et al. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med 2001;7:114-8
132. D'Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005;6:1152-9
133. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-51
134. Boyman O, Kovar M, Rubinstein MP, et al. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006;311:1924-7
135. Chen Z, Herman AE, Matos M, et al. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med 2005;202:1387-97
136. Green EA, Choi Y, Flavell RA. Pancreatic lymph node-derived CD4+CD25+ Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 2002;16:183-91